Vriglib-PM Tablet SR
Marketer
Vridam Healthcare Pvt Ltd
Salt Composition
Glibenclamide (5mg) + Metformin (500mg) + Pioglitazone (15mg)
Overview Vriglib-PM Tablet SR
Diabetol-Duo SR tablets are antidiabetic medications, a combination therapy for adult type 2 diabetes. They regulate blood glucose. Take Diabetol-Duo SR with food, consistently at the same time daily for optimal results. Dosage is determined by your physician and may adjust based on blood sugar monitoring. Continue taking this medication, even with controlled blood sugar, as discontinuation without medical supervision can elevate blood glucose, potentially causing kidney damage, vision loss, neuropathy, and limb complications. This medication is part of a comprehensive diabetes management plan, incorporating diet, exercise, and weight management as directed by your doctor. Lifestyle significantly impacts diabetes control. Hypoglycemia (low blood sugar) is a common side effect; learn its symptoms (sweating, dizziness, headache, tremors) and management. Maintain regular meals and carry a fast-acting glucose source. Alcohol increases hypoglycemia risk and should be avoided. Other possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. Do not use if you have type 1 diabetes, diabetic ketoacidosis, or severe kidney/liver disease. Inform your doctor of any heart history before starting treatment. It may be unsuitable for pregnant or breastfeeding individuals. Regular blood glucose checks and potential blood tests (blood cell counts, liver function) are necessary.
Uses of Vriglib-PM Tablet SR
Managing type 2 diabetes
Major Benefits of Vriglib-PM Tablet SR:
Consume this medication precisely as directed by your physician, adhering to both the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Vriglib-PM Tablet SR with a meal.
Common Side effects of Vriglib-PM Tablet SR:
- Anemia (low number of red blood cells)
- Hypoglycemia (low blood glucose level)
- Diarrhea
- Weight gain
- Headache
- Nausea
- Vomiting
- Blood in urine
- Erectile dysfunction
- Visual disorder
- Abdominal pain
How to use Vriglib-PM Tablet SR:
Follow your doctor's instructions precisely regarding dosage and treatment length for Vriglib-PM Tablet SR. Ingest the tablet whole; avoid crushing, chewing, or breaking it. Administer this medication with food.
How Vriglib-PM Tablet SR works:
Vriglib-PM SR tablets contain a triple-action antidiabetic formulation: glibenclamide, metformin, and pioglitazone. These medications employ distinct mechanisms to enhance blood glucose management when monotherapy or dual therapy proves insufficient. Glibenclamide, a sulfonylurea, stimulates pancreatic insulin secretion, thereby reducing blood sugar levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, retarding intestinal glucose absorption, and augmenting insulin sensitivity. Pioglitazone, a thiazolidinedione, further improves insulin responsiveness.
SAFETY ADVICE
AlcoholUNSAFE
Avoid alcohol while taking Vriglib-PM Tablet SR.
PregnancyCONSULT YOUR DOCTOR
Using Vriglib-PM Tablet SR during pregnancy poses a confirmed risk to the fetus. Its use should be avoided except in extremely rare, life-threatening circumstances where the potential benefits clearly outweigh the known hazards. Physician consultation is essential.
Breast feedingUNSAFE
Extended-release Vriglib-PM tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant toxicity from this medication.
DrivingCONSULT YOUR DOCTOR
The effect of Vriglib-PM Tablet SR on driving ability is undetermined. Refrain from operating a vehicle if you experience symptoms impairing concentration or reaction time.
KidneyUNSAFE
Use of Vriglib-PM SR tablets is likely inadvisable for individuals with impaired kidney function and should be omitted. Seek medical advice.
LiverCAUTION
Patients with liver impairment should use Vriglib-PM Tablet SR cautiously, potentially requiring dosage modification under medical supervision. Vriglib-PM Tablet SR is contraindicated in those with severe hepatic dysfunction.
What if you forget to take Vriglib-PM Tablet SR :
Should you forget a Vriglib-PM Tablet SR dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Vriglib-PM Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |





